Skip to main content

FDA in 2017: What to Expect?

Jan
24
2017

Date: January 24, 2017

Time: 5:30PM

Location: New York, NY

Topics

  • FDA in 2017: What to Expect?

Join Mintz Levin and ML Strategies as we look ahead to 2017 and discuss priorities of the FDA and the potential impact on companies in the health care and life sciences industries.

Topics will include:
  • President-elect Trump’s plans for FDA reform
  • Expected health care activity in the 115th Congress
  • Changing FDA regulatory priorities
  • Practical implications for industry

 

Speakers

Joanne S. Hawana counsels global Mintz clients on regulatory and distribution-related considerations for new FDA-regulated products. She also advises clients on the business impacts of new federal and state actions on food, drugs, cosmetics, electronic nicotine systems, and medical devices.
Rodney L. Whitlock is Vice President of ML Strategies and a health care policy professional. Rodney has over 20 years of experience working with the US Congress as a health policy advisor. He also served as Acting Health Policy Director for Finance Committee Chairman Chuck Grassley.
Bethany J. Hills is recognized for her experience and insight on FDA matters. At Mintz, she advises health care providers on pre- and post-market issues. Bethany also helps international and US companies enter and navigate the US health care market.